drugset / Trial / NCT00217711

Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

NCT00217711

Phase 1/2 Completed 23 enrolled Swiss Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine when given together with oxaliplatin and irinotecan and to see how well they work in treating patients with advanced or metastatic colorectal cancer that cannot be removed by surgery.

Timeline

Start
2005-05
Primary completion
2007-08
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Capecitabine Small molecule 1400 mg/m2 Oral
Comparator Irinotecan Small molecule 100 mg/m2 Intravenous
Comparator Oxaliplatin Small molecule 70 mg/m2 Intravenous

Indications